登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
ClinicalTrials.gov 上登记的一项肝豆状核变性开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 3
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
- 研究中心首都医科大学附属北京佑安医院Beijing Youan Hospital, Capital Medical University北京医院页面
- 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07465718,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
8 岁 至 未注明;性别:不限
登记记录的入选字段
Participants 12 years or older at screening, Model for End stage Liver Disease (MELD) score of greater than or equal to 12.
排除标准第 6 条
Participants 8 to 11 years at screening, Model for Pediatric End stage Liver Disease (PELD) of greater than or equal to 10
排除标准第 7 条
Received no prescribed chelator therapy [a] for the treatment of WD (chelator-naïve); zinc salts are permitted for no more than 28 days prior to the start of screening assessments, and these participants must be symptomatic.
入选标准第 6 条
Hemoglobin of less than or equal to 9 g/dL.
排除标准第 8 条
Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m²
排除标准第 9 条
Alanine aminotransferase greater than 5 times upper limit of normal (ULN).
排除标准第 11 条
Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus or seropositivity for human immunodeficiency virus (HIV).
排除标准第 16 条
Female participants of childbearing potential, currently pregnant, currently nursing, or planning a pregnancy during study period.
排除标准第 18 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07465718,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participant is aged 8 years or older and is willing and able to give informed consent for participation in the study, or by a parent/legally authorized representative (LAR) and assent obtained (in accordance with local regulations) for any participant less than the age of majority (e.g. less than 18 years of age, depending on local requirements). Participant has a body weight of at least 25 kg at screening. Participant has a diagnosis of WD, as defined by a Leipzig score of greater than or equal to 4. Note that historical test results can be used for the diagnosis. Participant has either: Received no prior prescribed therapy [a] for the treatment of WD (treatment-naïve), or Received no prescribed chelator therapy [a] for the treatment of WD (chelator-naïve); zinc salts are permitted for no more than 28 days prior to the start of screening assessments, and these participants must be symptomatic. Able and willing to comply with study procedures and requirements, as described in the informed consent. Adequate venous access to allow collection of required blood samples. Willing to comply with low copper diet for the duration of the study. Participant requires treatment for WD, in the opinion of the Investigator. Participant is able to take the study medication as prescribed, in the opinion of the Investigator.排除标准:Exclusion Criteria:
Any known contraindications for treatment with DPA. Any known contraindications for treatment with TETA 4HCl. Unable to swallow tablets/capsules independently or considered high risk for aspiration, in the opinion of the Investigator Acute liver failure (ALF) or at high risk of ALF, in the opinion of the Investigator. Decompensated hepatic cirrhosis, in the opinion of the Investigator. Participants 12 years or older at screening, Model for End stage Liver Disease (MELD) score of greater than or equal to 12. Participants 8 to 11 years at screening, Model for Pediatric End stage Liver Disease (PELD) of greater than or equal to 10 Hemoglobin of less than or equal to 9 g/dL. Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m² Nephritis or nephrotic syndrome, in the opinion of the Investigator. Alanine aminotransferase greater than 5 times upper limit of normal (ULN). Severe pulmonary disease requiring home nebulization and/or home oxygen therapy. Clinically significant gastrointestinal bleed within past 6-months. Neurological disease requiring either nasogastric feeding or intensive inpatient medical care. Active or history of seizures requiring anti-epileptics within 6 months prior to informed consent. Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus or seropositivity for human immunodeficiency virus (HIV). Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the collection or interpretation of the study results. Female participants of childbearing potential, currently pregnant, currently nursing, or planning a pregnancy during study period. Female participants of childbearing potential, unable or unwilling to use a reliable form of contraceptive throughout the study. Male participants, unable or unwilling to use a reliable form of contraceptive throughout the study. Participant is not willing to comply with the prohibited medication requirements for the study. In the opinion of the Investigator, the participant is likely to be non-compliant or uncooperative for the required study visits or study assessments, or has any disease, disability, illness or abnormal laboratory values that could compromise patient safety or interfere with the collection or interpretation of study results.
引自 ClinicalTrials.gov, NCT07465718, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07465718,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。